Adnexus Nixes IPO Route, Opts For $430M BMS Exit Sep. 25, 2007 By Donna Young Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today)Read More
RSS